Cytori Therapeutics to Voluntarily Delist From the Frankfurt Stock Exchange to Consolidate Trading on the NASDAQ Global Market

28-Jun-2007

Cytori Therapeutics is voluntarily delisting from the Frankfurt Stock Exchange (FSE). The move is primarily in response to the significant shift in trading volume since December 2005 from the FSE toward the NASDAQ Global Market, where Cytori will maintain its primary listing. Cytori's last day of trading on the FSE will be September 25, 2007. Following this date, shares owned in Germany, the United States, or elsewhere may continue to be traded through the NASDAQ Global Market under the symbol CYTX.

"This is an opportunity to consolidate trading on one of the most efficient international stock markets, the NASDAQ Global Market, where the vast majority of our shares now trade, while simultaneously reducing redundant fees and expenses associated with a dual listing," said Mark Saad, Chief Financial Officer for Cytori. "All our shareholders will be optimally supported by the single listing and the European investment community will continue to be a priority for us, given our global reach as a regenerative medicine company."

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...